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Brief Summary: 26 
This study draws on data from over 5000 European adults of 60+ years and shows 27 
that better folate and related B-vitamin status may have a positive impact on mental 28 
health in older adults.  29 
 30 
Abstract 31 
Objectives: Mental health disorders are major contributors to disease burden in older 32 
people. Deficient status of folate and the metabolically related B-vitamins may be 33 
implicated in these conditions. This study aimed to investigate folate, vitamin B12, 34 
vitamin B6 and riboflavin in relation to depression and anxiety in aging and also 35 
considered the role of fortified foods as a means of optimizing B-vitamin status and 36 
potentially reducing the risk of these mental health disorders.  37 
Design: The TUDA aging study was a cross-sectional cohort study.  38 
Setting and Participants: Community-dwelling adults (n = 5186; ≥ 60 years) recruited 39 
from two jurisdictions within the island of Ireland from 2008 to 2012. 40 
Measures: Depression and anxiety were assessed using the Centre for 41 
Epidemiological Studies Depression (CES-D) and the Hospital Anxiety and 42 
Depression (HAD) scales, respectively. The following B-vitamin biomarkers were 43 
measured: red blood cell folate, serum total vitamin B12, plasma pyridoxal-5-44 
phosphate (PLP; vitamin B6) and erythrocyte glutathione reductase activation 45 
coefficient (EGRac; riboflavin). 46 
Results: Biomarker values in the lowest 20% of status for folate (Odds Ratio (OR) 47 
1.79; 95% CI 1.23-2.61), vitamin B6 (OR 1.45; 1.01-2.06) or riboflavin (OR 1.56; 1.10-48 
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2.00), but not vitamin B12, were each associated with an increased risk of depression 49 
(CES-D score ≥16). Correspondingly, B-vitamin fortified foods if consumed daily were 50 
associated with a reduced risk depression (OR 0.54; 0.41-0.70). A deficient status of 51 
vitamin B6 (OR 1.73; 1.07-2.81), but not other vitamins, was associated with increased 52 
anxiety.  53 
Conclusions/Implications: Better B-vitamin status may have a role in impacting 54 
positively on mental health in older adults. Regular intake of fortified foods can provide 55 
a means of optimizing B-vitamin status and thus could contribute to reducing 56 
depression. If confirmed by a randomized trial, these results may have implications for 57 
nutrition and mental health policy, and thus quality of life, in older people. 58 
  59 
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Introduction 60 
Globally the population is aging and by 2050 the number of people aged ≥60 years is 61 
predicted to reach 2.1 billion.1 Mental health disorders are a leading cause of disability 62 
and ill health in older age,2 affecting an estimated 20% of adults ≥60 years worldwide.3 63 
Given the considerable human and economic cost of mental health conditions and the 64 
generally poor response rates to costly pharmacological treatments,4,5 there is much 65 
interest in the potential roles of certain dietary components as modifiable risk factors 66 
for depression. Folate and vitamin B12 have received particular attention in this 67 
regard.6 These B-vitamins have interrelated roles within one-carbon metabolism, 68 
where folate in the form of 5 methyltetrahydrofolate, and vitamin B12 in the form of 69 
methylcobalamin, are required for the remethylation of homocysteine to methionine 70 
which subsequently forms S-adenosylmethionine (SAM).7 SAM, in turn, is the 71 
essential methyl donor required for the production of monoamine neurotransmitters, 72 
phospholipids and nucleotides.8  73 
Historically, clinical deficiencies of folate and vitamin B12 were associated with 74 
a range of neuropsychiatric symptoms, including depression,9-11 raising the possibility 75 
that optimizing relevant B-vitamin intake and status could be protective. Research to 76 
date in this area has however focused predominantly on folate, and to a lesser extent 77 
vitamin B1212 whereas related B-vitamins - vitamin B6 and riboflavin - also required 78 
for one-carbon metabolism have received much less attention. The aim of this study 79 
therefore was to investigate biomarker status of all relevant B-vitamins - folate, vitamin 80 
B12, vitamin B6 and riboflavin - in relation to mental health in a well characterized 81 
cohort of 5186 older adults born in Ireland. Furthermore, this study considered the role 82 
of fortified foods as a means of optimizing B-vitamin status, and potentially reducing 83 
the risk of depression and anxiety, in older adults.  84 
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 Methods 85 
Study design and participants 86 
The study involved new analysis of data from the TUDA aging cohort study 87 
(ClinicalTrials.gov Identifier: NCT02664584). As described in detail elsewhere,13 5,186 88 
community-dwelling adults aged ≥60 years were recruited between 2008 and 2012 89 
from two jurisdictions within the island of Ireland - Northern Ireland (United Kingdom, 90 
UK) and the Republic of Ireland. The TUDA study initially aimed to investigate the role 91 
of nutrition and lifestyle factors in the etiology of common age-related diseases, 92 
namely, dementia, osteoporosis and cardiovascular disease. Participants were 93 
recruited in both jurisdictions using standardized protocols by centrally trained staff, 94 
either from general practice or hospital outpatient clinics, and deemed suitable if they 95 
were born on the island of Ireland and were without a diagnosis of dementia. For the 96 
current study, participants receiving vitamin B12 injections were excluded from the 97 
analysis (Fig. 1).  98 
Ethical approval was granted by the Office for Research Ethics Committees 99 
Northern Ireland (ORECNI; reference 08/NI/RO3113), with corresponding approvals 100 
from The Northern and Western Health and Social Care Trusts in Northern Ireland, 101 
and the Research Ethics Committee of St James Hospital and The Adelaide and 102 
Meath Hospital in Dublin. All participants provided written informed consent.  103 
 104 
Neuropsychiatric assessment 105 
During the participant appointment, depression was assessed using the Centre 106 
for Epidemiological Studies Depression (CES-D) scale, which is a 20 item self-107 
reported questionnaire, with a minimum score of 0 (no symptoms of depression) and 108 
maximum score of 60 (significant symptoms of depression). A score of ≥16 was used 109 
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as a cut-off value suggestive of clinical depression.14 Anxiety was assessed using the 110 
7 item Hospital Anxiety and Depression (HAD) scale, with a minimum score of 0 111 
(suggestive of no symptoms of anxiety) and a maximum score of 21 (significant 112 
anxiety). A score ≥11 was used as a cut-off value for probable anxiety.15 113 
For the purpose of the current analysis, cognitive function was assessed using 114 
the Folstein Mini-Mental State Examination (MMSE),16 a short, structured cognitive 115 
test. The maximum score achievable is 30, with a score <25 indicating a possibility of 116 
cognitive impairment and a score <20 indicating dementia.  117 
 118 
Blood sampling and laboratory analysis  119 
A non-fasting blood sample was obtained and analyzed on the day of sampling 120 
for routine biomarkers of health in participating hospital laboratories. For research 121 
biomarkers, all sample preparation and fractionation was carried out within 4 hours of 122 
collection and fractions were stored at -70 °C (for up to five years) for batch analysis 123 
at the end of the study. B-vitamins were analyzed centrally in laboratories in Dublin 124 
(vitamin B12, folate, homocysteine) or Coleraine (vitamin B6, riboflavin) using 125 
established methods.  Red blood cell (RBC) folate and serum total vitamin B12 were 126 
measured by microbiological assay using Lactobacillus casei and Lactobacillus 127 
leichmanni, respectively.17,18 Plasma homocysteine was measured by fluorescence 128 
polarization immunoassay.19 Vitamin B6 status (plasma pyridoxal-5-phosphate, PLP) 129 
was analyzed by HPLC with fluorescence detection.20 Riboflavin status was measured 130 
by erythrocyte glutathione reductase activation coefficient (EGRac), a functional assay 131 
that measures the activity of glutathione reductase before and after in-vitro reactivation 132 
with its prosthetic group flavin adenine dinucleotide (FAD), the active cofactor form of 133 
riboflavin; results are reported as a ratio, a higher EGRac ratio indicates lower 134 
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riboflavin status.21 For each assay, quality controls were provided by the repeated 135 
analysis of pooled samples covering a wide range of values. 136 
 137 
Dietary assessment 138 
Dietary information on habitual intake of specified foods (for the purpose of this 139 
paper, B-vitamin fortified foods) was collected using a researcher-assisted food 140 
frequency questionnaire (FFQ), previously validated for B-vitamin intake against B-141 
vitamin biomarkers.22  Using a 7-item section for fortified foods (from a larger FFQ 142 
used in the TUDA study), brand names of fortified food products were collected so that 143 
up-to-date details on relevant nutrient profiles could be obtained. Using this approach, 144 
participants were categorized according the number of portions of fortified food 145 
consumed per week. A small number of participants (n = 110; 2.2%) could not be 146 
classified as regards fortified food intake and/or supplement use and are not included 147 
in this analysis. 148 
 149 
General health, lifestyle and biophysical measures 150 
Health and lifestyle information was gathered using a researcher-assisted, 151 
questionnaire which included information on smoking, alcohol, medical history and use 152 
of prescription drugs, including antidepressant medications. To facilitate the accuracy 153 
of recorded drugs and vitamin supplements, participants were asked to bring these 154 
items to their appointment for inspection by the researcher. Anthropometric 155 
measurements were recorded (including weight, height, waist and hip) and blood 156 
pressure measurements were taken in accordance with standard operating 157 
procedures by trained researchers. The Timed Up-and-Go (TUG) test,23 the Physical 158 
Self-Maintenance Scale (PSMS) and the Instrumental Activities of Daily Living (IADL) 159 
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scale were used to assess functional mobility and general ability of participants. Socio-160 
economic status was measured as area-based deprivation by adopting a novel cross-161 
jurisdictional appraoch, whereby geo-referenced address-based information was used 162 
to map and link participants to official socioeconomic indicators of deprivation within 163 
Northern Ireland (UK) and the Republic of Ireland, as previously described in detail.13  164 
 165 
Statistical Analysis 166 
All statistical analysis was performed using SPSS software (Statistical Package 167 
for Social Sciences, Version 23.0, SPSS UK Ltd., Chersey, United Kingdom). Data 168 
were checked for normality and log-transformed as appropriate. Analysis of 169 
covariance with Bonferroni post hoc test was used for analysis of continuous data and 170 
chi-squared tests were used for categorical variables. Relationships of demographic, 171 
clinical and lifestyle factors with depression (CES-D score) and anxiety (HAD score) 172 
were investigated using multiple linear regression analysis. The risk of depression 173 
(CES-D score ≥16) and anxiety (HAD score ≥11) in relation B-vitamin biomarker status 174 
was determined using logistic regression. For this purpose, B-vitamin biomarkers were 175 
examined in quintiles ranging from the highest 20% (reference category) to lowest 176 
20% of values, and the model was adjusted for relevant co-variates. The associations 177 
of B-vitamin fortified food intake with risk of depression (CES-D score ≥16) and anxiety 178 
(HADS score ≥11) were also determined using logistic regression, with adjustment for 179 
relevant co-variates; the reference category was non-consumers, against which the 180 
remaining categories (low, medium and high fortified food frequencies) were 181 
compared.  182 
 183 
Results 184 
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General characteristics 185 
The general characteristics of the study population are described in Table 1. 186 
Participants were predominantly female (67%), the majority were fortified food 187 
consumers (72%) and 11% were B-vitamin supplement users. Overall, higher rates of 188 
depression (CES-D score ≥16.0) and anxiety (HAD score ≥11.0) were recorded in 189 
females compared to males; likewise, self-reported depression and anxiety were also 190 
higher in females. B-vitamin biomarker status was generally lower, and homocysteine 191 
concentrations higher, in men compared to women. Although mean B-vitamin 192 
biomarker concentrations fell within normal reference ranges, some evidence of 193 
deficiency (using accepted laboratory cut-offs) was identified for specific B-vitamin 194 
biomarkers (data not shown): folate (RBC folate 2.3%); vitamin B12 (serum B12 195 
11.6%); vitamin B6 (PLP 12.2%); riboflavin (EGRac 48.6%).  196 
 197 
Relationships of demographic, clinical and lifestyle factors with depression and anxiety 198 
The relationship of clinical and lifestyle factors with depression (CES-D score) 199 
and anxiety (HAD score) was examined by linear regression (Supplemental Table 1). 200 
The following factors were significantly associated with depression: female sex (β = 201 
0.04, P = .008), socioeconomic status (β = 0.09, P <.001), physical frailty (β = 0.19, P 202 
< .001), living alone (β = 0.08, P <.001), antidepressant usage (β = 0.21, P < .001), 203 
previous ischemic attack (β = 0.04, P = .02) and smoking (β = 0.05, P =.001), whereas 204 
age (β = - 0.10 P <.001) and education (β = - 0.06, P <.001) were negatively related 205 
to depression. The following factors were identified as being positively associated with 206 
anxiety: female sex (β = 0.08, P <.001), socioeconomic status (β = 0.08, P <.001), 207 
hypertension (β = 0.04, P = .027) and anti-depressant usage (β = 0.18, P <.001), 208 
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whereas age (β = -0.138, P <.001), education (β = -0.10, P <.001) and BMI (β = -0.05, 209 
P <.001) were inversely related to anxiety. 210 
 211 
B-vitamin biomarker status in relation to depression and anxiety 212 
The associations of B-vitamin biomarker status with risk of depression (CES-D 213 
score ≥16) was examined after adjustment for the above co-variates and vitamin 214 
supplement use (Fig. 2). Each B-vitamin was examined in quintiles of biomarker 215 
status; the reference category was set at the highest 20% of values. Compared with 216 
the reference category, the lowest quintile of folate (Odds Ratio (OR) 1.79; 95% CI 217 
1.23-2.61, P = .002), vitamin B6 (OR 1.45; 1.01-2.06, P = .043) or riboflavin (OR 1.56; 218 
1.10-2.00, P = .012) status was associated with increased risk of depression. No 219 
significant relationship of serum total B12 was observed with depression (P = 0.577). 220 
Similarly, the relationship of B-vitamins with anxiety was examined in quintiles of 221 
biomarker status (data not shown). After adjustment for relevant co-variates (i.e. age, 222 
gender, anti-depressant drug usage, education, BMI, socioeconomic status and 223 
hypertension) and vitamin supplement use, only low/deficient status of B6 - but not 224 
other B-vitamins - was associated with an increased risk of anxiety (OR 1.73; 1.07-225 
2.81, P = .024). 226 
 227 
B-vitamin intakes, biomarker status and risk of depression or anxiety 228 
The influence of B-vitamin fortified food and supplement intake on B-vitamin 229 
biomarker status was examined (Table 2). Participants were categorized by fortified 230 
food intake (0, low, medium, high) and supplement usage; ‘non-consumers’ did not 231 
consume fortified foods or supplements and hence depended on natural food sources 232 
of B-vitamins only. As dietary intake of B-vitamin fortified foods increased, biomarker 233 
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status of each vitamin increased in a stepwise manner, with the highest B-vitamin 234 
biomarker status being observed in those participants who consumed the highest 235 
intakes of fortified foods (i.e. at least once daily) and in those taking B-vitamin 236 
supplements. Supplement users were identified on the basis of their reported current 237 
use of supplemental B vitamins in tablet form (irrespective of fortified food) and 238 
accounted for 10.8% of overall TUDA sample. A small number of participants (n = 110; 239 
2.2%) could not be classified as regards fortified food intake and supplement use and 240 
thus were excluded from this part of the analysis. Fortified breakfast cereals (65%), 241 
spreads (55 %) and drinks (20 %) were the most commonly consumed fortified foods 242 
within this cohort (data not shown). 243 
The risk of depression was examined in relation to B-vitamin fortified food intake 244 
(Fig. 3); for this purpose, the reference category was ‘non-consumers’ i.e. no fortified 245 
food or supplement usage. High fortified food intake (> 1 portion per day) was 246 
associated with significantly lower depression (OR 0.54; 95% CI 0.41-0.70, P <.001). 247 
After adjustment for relevant co-variates (i.e. age, gender, anti-depressant medication, 248 
education, vitamin supplement usage, smoking status, physical frailty, living alone, 249 
socioeconomic status and transient ischemic attack) and fortified food intake, B-250 
vitamin supplement usage was not associated with risk of depression (OR 0.941; 0.68-251 
1.30, P = .712). No significant relationship was identified between B-vitamin fortified 252 
food intake (OR 0.97; 0.69-1.36, P = .861) or supplement usage (OR 0.99; 0.64-1.54, 253 
P = .974) and anxiety.  254 
 255 
Discussion 256 
This study is the first large cross sectional study to investigate biomarker status 257 
of all four B-vitamins involved in one-carbon metabolism in relation to depression and 258 
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anxiety in older adults. The findings suggest that low biomarker status of folate, vitamin 259 
B6 or riboflavin, but not vitamin B12, were each independently associated with 260 
increased depression. Correspondingly, consuming at least one portion per day of B-261 
vitamin fortified food was associated with lower depression (by 50% relative to non-262 
consumers). Only deficient status of vitamin B6 (but not the other B-vitamins) was 263 
associated with higher risk of anxiety, and no significant relationship of fortified food 264 
with anxiety was shown. 265 
The current results estimated that having RBC folate concentrations in the 266 
lowest 20% was associated with an increased risk of depression (by almost 80%), 267 
adding to the considerable body of evidence linking low folate with depression. 268 
Likewise, published meta-analyses of observational studies in adults reported that low 269 
biomarker status of folate was associated with between 23%12 and 42%24 increased 270 
risk of depression. The stronger relationship of folate with depression identified in the 271 
current study compared with the aforementioned studies,12,24 may be explained to 272 
some extent by the use of RBC folate. RBC folate is widely considered to be a better 273 
index of long-term folate status, compared to plasma or serum folate as it parallels 274 
liver concentrations (accounting for about 50% of total body folate) and is thus 275 
considered to represent tissue folate stores, whereas serum folate is the earliest 276 
indicator of folate exposure and reflects recent dietary intake.7,25 The evidence linking 277 
folate with depression is however not entirely consistent. The Chicago Health and 278 
Aging Study (CHAP) (n = 3503) and the Quebec longitudinal study on nutrition and 279 
Aging (NuAge) (n = 1368) found no association of folate with depression; however 280 
these observations were based on dietary intakes only with no corresponding folate 281 
biomarker data.26,27 Furthermore, the studies were conducted in regions with 282 
mandatory folic acid fortification policies, where more optimal folate status throughout 283 
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the population would make a relationship with depression less likely. The current study 284 
found no association of vitamin B12 with depression, which is in line with the findings 285 
from one large cohort study (n = 2,524) conducted in the USA,28 but at odds with other 286 
research which reported inverse associations of vitamin B12 intake26,27 or 287 
biomarkers29 with depression. The explanation for such discrepancy in the evidence 288 
linking vitamin B12 with depression is unclear, but may possibly relate to differences 289 
in B12 status among populations under investigation or methodological variation 290 
among studies, including the use of different B12 biomarkers to measure status, 291 
especially considering that no consensus exists as to the best biomarker for assessing 292 
B12 status in the laboratory.30  293 
Low status of vitamin B6 or riboflavin were each significantly associated with 294 
depression. Likewise, previous studies have reported inverse associations of vitamin 295 
B6 biomarkers with depression.31 In contrast to the other relevant B-vitamins, riboflavin 296 
has received very little attention as regards its potential role in depression, with 297 
previous evidence limited to one early study which reported that 27% of patients 298 
admitted to a psychiatric inpatient unit had riboflavin deficiency,32 whilst a recent study 299 
showed no significant relationship of dietary riboflavin intake with depression.33 The 300 
finding that both vitamins show similar relationships with depression is perhaps 301 
unsurprising. There is a well established metabolic dependency of vitamin B6 on 302 
riboflavin, in that the generation in tissues (via pyridoxine 5’phosphate oxidase) of the 303 
active B6 form, PLP, requires riboflavin in its co-factor form flavin mononucleotide 304 
(FMN). This interrelationship in humans was previously confirmed by showing that 305 
riboflavin supplementation of older adults not only improved riboflavin biomarker 306 
status, but also enhanced vitamin B6 concentrations, suggesting that riboflavin may 307 
be the more limiting nutrient.34  308 
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In the current study, low/deficient vitamin B6 status was associated with an 309 
increased risk of anxiety, while no significant associations with anxiety were found for 310 
any other B-vitamin biomarkers or fortified foods. The findings are generally in line with 311 
those of the Hordaland Homocysteine Study (n = 5948) which also reported no 312 
significant relationships of folate or vitamin B12 with anxiety in Norwegian adults.35 313 
Few previous studies have investigated vitamin B6 in relation to anxiety and the 314 
evidence is unclear, although one randomized trial in 60 patients observed short term 315 
benefits in symptoms of anxiety in response to a supplement containing vitamin B6 316 
(combined with vitamin B12 and folate) in patients suffering from depression,36 317 
perhaps suggesting potential benefits of optimizing B6 status in this patient group. In 318 
line with the conclusions of a recent meta-analysis, we observed a positive association 319 
of anxiety with hypertension in the current study, the mechanism for which has been 320 
previously reviewed but remains unclear.37 Further work would be required to 321 
investigate whether vitamin B6 plays a role in this complex relationship.   322 
The current results not only showed that low biomarker status of specific B-323 
vitamins was associated with a higher risk of depression, but importantly suggested 324 
(for the first time) the potential for fortified foods to contribute to reducing depression 325 
in older age. Fortified foods are known to provide a highly bioavailable source of B-326 
vitamins, particularly folate,7 and their contribution to optimal B-vitamin biomarker 327 
status among adults (not taking B-vitamin supplements) has previously been 328 
reported.22 The current results suggest that regular consumption of fortified foods, by 329 
improving B-vitamin biomarkers, may provide a practical means of reducing the risk of 330 
depression in older adults.  Indeed the findings, showing a potential benefit of fortified 331 
foods in relation to mental health, may contribute to the current risk-benefit debate 332 
surrounding mandatory fortification with folic acid, and specifically the issue of whether 333 
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there are any benefits to older people from a folic acid fortification policy directed 334 
primarily at preventing neural tube defects in women of reproductive age.38 335 
The biological mechanism explaining these and previous results linking folate 336 
and related B-vitamins with depression is not known, but invariably must relate to their 337 
roles in one-carbon metabolism. In particular, these B-vitamins are required for 338 
methylation reactions; lower status may thus reduce the methylation of 339 
neurotransmitters.6 Furthermore, folate is required for monoamine synthesis and lower 340 
concentrations of monoamine metabolites in cerebral spinal fluid have been found in 341 
folate deficient patients suffering from depresssion.8 Additionally, the active form of 342 
vitamin B6 (PLP) is the cofactor for aromatic L-amino acid decarboxylase in the 343 
tryptophan serotonin pathway, thus deficient B6 status (and/or riboflavin required to 344 
generate PLP in tissues)34 may lead to reduced concentrations of serotonin.39  345 
This study had both strengths and limitations. Although the TUDA study is one 346 
of the largest and most comprehensively characterized cohorts of its kind, its cross-347 
sectional design means that the possibility of residual confounding and reverse 348 
causality cannot be excluded. Also, the data have been derived from only two 349 
jurisdictions within Europe, Ireland and the UK, therefore the results may not 350 
necessarily be generalizable to other populations. Furthermore the CES-D scale used 351 
in this study to assess depression, while widely considered to have an acceptable 352 
screening accuracy in primary care settings, is not as robust as certain other 353 
diagnostic instruments and this may have limited the interpretation of the findings to 354 
some extent.40 However, this is the first human study to investigate the associations 355 
of all relevant B-vitamin biomarkers (including riboflavin, rarely assessed in cohort 356 
studies or nutritional surveys) with depression and anxiety in older adults, and thus 357 
allowed an in-depth examination of the role of one-carbon metabolism in mental 358 
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health. Finally, this is the first study to have considered the potential role of fortified 359 
foods as a practical means of reducing depression in older age. 360 
 361 
Conclusions/Relevance 362 
This study shows that lower biomarker status of folate or vitamin B6 or riboflavin 363 
was associated with depression in older adults, while deficient status of vitamin B6 364 
was associated with anxiety. Higher intakes of B-vitamin fortified foods (e.g. fortified 365 
breakfast cereals) or B-vitamin supplement use resulted in the achievement of optimal 366 
B-vitamin biomarker status, whereas fortified foods consumed daily were associated 367 
with lower depression. Further work in the form of well-designed randomized 368 
controlled trials, investigating relevant B-vitamins and in populations with sub-optimal 369 
B-vitamin status, are needed to confirm these observational findings. If confirmed, 370 
these results may have implications for dietary recommendations and health policy 371 
involving low cost non-drug options to improve mental health and thus quality of life in 372 
older adults. 373 
 374 
Conflicts of Interest 375 
The authors have no financial or personal conflicts of interest. 376 
 377 
Acknowledgements  378 
The TUDA study was supported by the Irish Department of Agriculture, Food 379 
and the Marine and Health Research Board (under the Food Institutional Research 380 
Measure, FIRM) and from the Northern Ireland Department for Employment and 381 
Learning (under its Strengthening the All-Island Research Base initiative). 382 
17 
 
Sponsor's role: The funders of this research had no role in the design, methods, 383 
subject recruitment, data collections, analysis and preparation of paper. 384 
The authors are grateful to all TUDA participants. 385 
 386 
18 
 
References 
1. United Nations Department of Economic and Social Affairs/Population Division. 
World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. 
United Nations, 2015. 
2. Andreas S, Schulz H, Volkert J, Dehoust M et al. Prevalence of mental disorders 
in elderly people: the European MentDis_ICF65+ study. Br J Psychiatry 
2016;210:125-131. 
3. World Health Organisation. .Mental health and older adults. 
http://www.who.int/mediacentre/factsheets/fs381/en/.Accessed on April 2016. 
4. Almeida OP, Flicker L, Hankey GJ, Yeap BB et al. Depression, Frailty, and All-
Cause Mortality: A Cohort Study of Men Older than 75 Years. J Am Med Dir Assoc 
2015;16:296-300. 
5. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA et al. Acute and longer-term 
outcomes in depressed outpatients requiring one or several treatment steps: a 
STAR*D report. Am J Psychiatry 2006;163:1905-1917. 
6. Moore K, Hughes CF, Ward M, Hoey L et al. Diet, nutrition and the ageing brain: 
current evidence and new directions. Proc Nutr Soc 2018;1-12. 
7. Bailey LB, Stover PJ, McNulty H, Fenech MF et al. Biomarkers of Nutrition for 
Development-Folate Review. J Nutr 2015;145:1636-1680. 
8. Bottiglieri T, Reynolds EH. Folate and Neurological Disease. In: LB Bailey, eds. 
Folate in Health and Disease. 2nd Ed. Florida: CRC Press, 2005. 
19 
 
9. Carney MWP. Serum Folate Values In 423 Psychiatric Patients. Br Med J 
1967;4:512-516. 
10. Reynolds EH, Preece JM, Bailey J, Coppen A. Folate Deficiency in Depressive 
Illness. Br J Psychiatry 1970;117:287. 
11. Shorvon SD, Carney MWP, Chanarin I, Reynolds EH. The neuropsychiatry of 
megaloblastic anaemia. Br Med J 1980;281:1036. 
12. Petridou ET, Kousoulis AA, Michelakos T, Papathoma P et al. Folate and B12 
serum levels in association with depression in the aged: a systematic review and 
meta-analysis. Aging Ment Health 2016;20:965-973. 
13. McCann A, McNulty H, Rigby J, Hughes CF et al. Impact of area-level 
socioeconomic deprivation on the risk of cognitive dysfunction in older adults. J Am 
Geriatr Soc 2018;66:1269-1275. 
14. Radloff L, Locke B. The community mental health assessment survey and the 
CES-D Scale. . In: M Weissman, Myers J, Ross C, eds. Community surveys of 
psychiatric disorders. New Brunswick, NJ: Rutgers University Press, 1986. 
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta 
Psychiatr Scand 1983;67:361-370. 
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method 
for grading the cognitive state of patients for the clinician. J Psychiatr Res 
1975;12:189-198. 
20 
 
17. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate 
using cryopreserved, microtiter plate method. Methods Enzymol 1997;281:43-53. 
18. Kelleher BP, Broin S. Microbiological Assay for Vitamin-B-12 Performed in 96-
Well Microtitre Plates. J Clin Pathol 1991;44:592-595. 
19. Leino A. Fully automated measurement of total homocysteine in plasma and 
serum on the Abbott IMx analyzer. Clin Chem 1999;45:569-571. 
20. Bates CJ, Pentieva KD, Matthews N, Macdonald A. A simple, sensitive and 
reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma. 
1999;280:101-111. 
21. Powers HJ, Bates CJ, Prentice AM, Lamb WH et al. The relative effectiveness or 
iron and iron with riboflavin in correcting a microcytic anaemia in men and children in 
rural Gambia. 1983;37:413-425. 
22. Hoey L, McNulty H, Askin N, Dunne A et al. Effect of a voluntary food fortification 
policy on folate, related B vitamin status, and homocysteine in healthy adults. Am J 
Clin Nutr 2007;86:1405-1413. 
23. Podsiadlo D, Richardson S. The timed 'Up and Go': A test of basic functional 
mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142-148. 
24. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A 
meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 
2007;61:631-637. 
21 
 
25. Duffy ME, Hoey L, Hughes CF, Strain JJ et al. Biomarker responses to folic acid 
intervention in healthy adults: a meta-analysis of randomized controlled trials. Am J 
Clin Nutr 2014;99:96-106. 
26. Skarupski KA, Tangney C, Li H, Ouyang B et al. Longitudinal association of 
vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults 
over time. Am J Clin Nutr 2010;92:330-335. 
27. Gougeon L, Payette H, Morais JA, Gaudreau P et al. Intakes of folate, vitamin 
B6and B12and risk of depression in community-dwelling older adults: the Quebec 
Longitudinal Study on Nutrition and Aging. Eur J Clin Nutr 2016;70:380. 
28. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB. Serum folate, vitamin B-
12, and homocysteine and their association with depressive symptoms among U.S. 
Adults. Psychosom Med 2010;72:862-873. 
29. Kim JM, Stewart R, Kim SW, Yang SJ et al. Predictive value of folate, vitamin B-
12 and homocysteine levels in late-life depression. Br J Psychiatry 2008;192:268-
274. 
30. McNulty H, Hughes C. Assessing biomarker status of vitamin B12 in the 
laboratory: no simple solution. Ann Clin Biochem 2017;55:188-189. 
31. Merete C, Falcon LM, Tucker KL. Vitamin B6 is associated with depressive 
symptomatology in Massachusetts elders. J Am Coll Nutr 2008;27:421-427. 
32. Carney MW, Ravindran A, Rinsler MG, Williams DG. Thiamine, riboflavin and 
pyridoxine deficiency in psychiatric in-patients. Br J Psychiatry 1982;141:271-272. 
22 
 
33. Murakami K, Mizoue T, Sasaki S, Ohta M et al. Dietary intake of folate, other B 
vitamins, and omega-3 polyunsaturated fatty acids in relation to depressive 
symptoms in Japanese adults. Nutrition 2008;24:140-147. 
34. Madigan SM, Tracey F, McNulty H, Eaton-Evans J et al. Riboflavin and vitamin 
B-6 intakes and status and biochemical response to riboflavin supplementation in 
free-living elderly people. Am J Clin Nutr 1998;68:389-395. 
35. Bjelland I, Tell GS, Vollset SE, Refsum H et al. Folate, vitamin B-12, 
homocysteine, and the MTHFR 677C -> T polymorphism in anxiety and depression - 
The Hordaland Homocysteine Study. Arch Gen Psychiatry 2003;60:618-626. 
36. Lewis JE, Tiozzo E, Melillo AB, Leonard S et al. The Effect of Methylated Vitamin 
B Complex on Depressive and Anxiety Symptoms and Quality of Life in Adults with 
Depression. ISRN Psychiatry 2013;2013:621453. 
37. Pan Y, Cai W, Cheng Q, Dong W et al. Association between anxiety and 
hypertension: a systematic review and meta-analysis of epidemiological studies. 
Neuropsychiatr Dis Treat 2015;11:1121-1130. 
38. Mills J, Molloy AM, Reynolds E. Do the benefits of folic acid fortification outweigh 
the risk of masking vitamin B12 deficiency? BMJ 2018;360:k1334-k1334. 
39. Hensler J. Serotonin. In: Siegel GJ, Albers RW, Brady ST, Price DL, eds. Basic 
Neurochemistry: Molecular, Cellular and Medical Aspects. 7th Ed. Canada: Elsevier 
Academic Press, 2006. 
23 
 
40. Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for Depression in the 
General Population with the Center for Epidemiologic Studies Depression (CES-D): 
A Systematic Review with Meta-Analysis. PLoS One 2016;11:e0155431-e0155431. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
List of Figure Captions 
 
Fig.1. Flow Diagram and Study Design of the TUDA Aging Cohort 
 
Fig. 2. Risk of Depression in Relation to B-vitamin Biomarker Status 
RBC, red blood cell; PLP, pyridoxal 5-phosphate; EGRac, erythrocyte glutathione 
reductase co-efficient. Values are odds ratios for risk of CES-D score ≥16 with 95% 
CI relative to reference category, with adjustment for age, gender, anti-depressant 
drug usage, age finished education, vitamin supplement usage, smoking status, 
physical frailty (Timed up and go), living alone, area-based socioeconomic deprivation 
and transient ischemic attack. *P < .05 †P <.01.  
 
Fig. 3. Risk of Depression in Relation to B-vitamin Fortified Food Intake  
Values are odds ratios for risk of CES-D score ≥ 16 with 95% CI relative to reference 
category, with adjustment for age, gender, anti-depressant drug usage, age finished 
education, smoking status, physical frailty (Timed up and go), living alone, area-based 
socioeconomic deprivation and transient ischemic attack. *P < 0.001.   
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Table 1 
General Characteristics of TUDA Study Participants 
 Males  
(n = 1665) 
 Females  
(n = 3406) 
P* 
 
Age, mean (SD)  (year) 73.4 (8.0)  74.3 (8.4)  < .001 
Education, mean (SD) (years) 16.0 (3.2)  16.0 (2.9) .543 
Health and Lifestyle      
Instrumental Activities of Daily Living 24.1 (0.1)  24.1 (0.1) .895 
Physical Self Maintenance Score 23.1 (0.05)  22.9 (0.3) < .001 
Timed Up and Go (seconds) 14.1 (0.2)  14.0 (0.1) .461 
Living alone % (n) 22.4 (373)  39.2 (1335) < .001 
Current Smoker % (n) 11.6 (193)  12.1 (411) .651 
Alcohol (units/week) 8.8 (0.2)  2.5 (0.2) < .001 
Fortified Food Consumer % (n) 71.2 (1186)  71.7 (2443) .888 
B-vitamin Supplement User % (n) 9.8 (163)  11.4 (3820 .098 
Vitamin D Supplement User % (n) 32.1 (533)  55.3 (1867) < .001 
Socio-economic Status (most deprivation) % (n) 26.4 (429)  26.2 (867) .856 
Medical      
BMI (kg/m2) 28.4 (0.1)  27.7 (0.01) < .001 
   Waist to Hip ratio 0.97 (0.02)  0.88 (0.01) < .001 
Diabetes % (n) 18.7 (311)  9.6 (327) < .001 
Hyperlipidemia % (n) 55.3 (919)  52.1 (1774)  .037 
Hypertension % (n) 79.2 (1318)  68.1 (2318) < .001 
Previous Myocardial infarction % (n) 16.0 (266)  7.2 (244) < .001 
Previous Transient Ischemic Attack % (n) 8.1 (135)  8.4 (286)  .774 
Previous Stroke % (n) 11.4 (189)  5.8 (199) < .001 
Brain Health     
Depression (CES-D Score) 5.5 (0.2)  6.3 (0.1) .267 
Identified Depressed (CES-D Score ≥16)% (n) 8.3 (137)  12.0 (407) < .001 
  Self-reported depression % (n) 19.5 (325)  26.2 (893) < .001 
  Anti-depressant drugs % (n) 10.2 (169)  15.9 (542) < .001 
Anxiety (HAD score) 2.8 (0.1)  3.4 (0.1) .513 
Identified Anxious (HAD score ≥11) % (n) 3.7 (61)  5.6 (190) .004 
  Self-reported anxiety % (n)  15.9 (264)  24.4 (832) < .001 
Cognition (MMSE score) 27.0 (0.1)  27.1 (0.0) < .001 
  Cognitive impairment (MMSE <25) % (n) 11.9 (187)  13.5 (444)  .134 
Biomarker      
Red blood cell folate (nmol/L) 1043 (13.5)  1094 (9.2) .001 
Serum vitamin B12 (pmol/L) 263 (3.1)  288 (2.1) < .001 
Plasma vitamin B6 (PLP; nmol/L) 65.4 (1.0)  72.0 (0.7) < .001 
Riboflavin (EGRac) 1.34 (0.00)  1.33 (0.00)  .146 
Plasma total Homocysteine (µmol/L) 15.2 (0.1)  14.3 (0.1) < .001 
MTHFR  677TT genotype % (n) 11.9 (192)  12.2 (405)  .689 
TUDA, Trinity Ulster Department of Agriculture; MMSE, Mini Mental State Examination; CES-D, Centre 
for Epidemiologic Studies Depression; HAD, Hospital Anxiety and Depression Scale; PLP, pyridoxal 5-
phosphate; EGRac, erythrocyte glutathione reductase activation co-efficient; MTHFR 
methylenetetrahydrofolate reductase. Continuous variables presented as adjusted means (SEM) 
unless otherwise stated. 
*ANCOVA with Bonferroni post hoc tests on log-transformed data when applicable, with adjustment for 
age, BMI, smoking status, alcohol, anti-depressant medication usage, vitamin supplement usage and 
fortified food and categorical variables were assessed using χ² analysis
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Table 2  
B-vitamin Intakes from Fortified Food and Supplements in Relation to Biomarker Status 
RBC, red blood cell; PLP, pyridoxal 5-phosphate; EGRac, erythrocyte glutathione reductase activation co-efficient  
Data presented as median (25th, 75th percentiles). Differences were assessed using ANCOVA with Bonferroni post hoc tests on log-transformed 
data when applicable, controlling for age, gender, BMI and smoking. Values within a row without a common superscript symbol (‡, §, ||, **,††) are 
significantly different (P < 0.001). Normal reference ranges for the laboratory assay from lab where analysis was conducted: RBC folate >340 
nmol/L; Serum vitamin B12 >148pmol/L; Vitamin B6 ≥30 nmol/L; Riboflavin ≤1.3; Homocysteine <15µmol/L. 
*A small number of participants (n = 110; 2.2%) could not be classified as regards fortified food intake and supplement use and are not included 
in this analysis  
†Supplement User’ was identified as current user of supplemental B-vitamins in tablet form (irrespective of fortified food).  
 
 Non Consumer Fortified Food Consumer Supplement User † 
  Low consumer Medium consumer High consumer  
Servings of Fortified Foods/week 0 1-4 5-7 8+ 0-8+ 
TUDA Total n (%)* 1164 (23.0) 479 (9.5) 1049 (20.7) 1724 (34.0) 545 (10.8) 
Vitamin Biomarker      
RBC folate (nmol/L) 691 (525, 910)‡ 802 (612, 1089)§ 909 (664, 1238)|| 1138 (809, 1577)** 1554 (1034, 2023)†† 
Serum folate (nmol/L) 16.5 (11.1, 24.4)‡ 19.5 (14.2,28.9)§ 24.6 (163, 37.7)|| 34.0 (21.5, 57.0)** 51.1 (32.6, 77.5)†† 
Serum total vitamin B12 (pmol/L) 238 (174, 318)‡ 243 (180, 323)‡§ 260 (188, 336)*§ 271 (208, 361)|| 293 (213, 392)|| 
Plasma vitamin B6 PLP (nmol/L) 47.0 (31.9, 70.0)‡ 54.1 (37.5, 80.0)§ 60.8 (41.5, 87.6)|| 70.3 (47.5, 97.6)** 70.6 (39.0, 115.0)** 
EGRac (riboflavin status; ratio) 1.35 (1.25, 1.47)‡ 1.32 (1.22, 80.0)§ 1.28 (1.20, 1.38)|| 1.28 (1.20, 1.39)|| 1.24 (1.15, 1.34)** 
Homocysteine (µmol/L) 15.2 (12.2, 19.1)‡ 13.7 (11.4, 16.7)§ 13.7 (11.3, 17.1)§ 12.6 (10.7, 15.7)|| 12.2 (10.3, 15.0)|| 
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